Table 3.
Published clinical trials on bronchopulmonary dysplasia with placenta derived stem cells.
| Stem cells | Phase | Gestational age (weeks) | Mean age at treatment (days) | Mean birth weight (g) | Sample size, n | Study designs | Results | References | |
|---|---|---|---|---|---|---|---|---|---|
| Dosage | Route | ||||||||
| Allogeneic hAECs (ACTRN 12614000174684) |
I | 26 | 89 days | 795 | 6 | 1x106/kg | Intravenous | 5 alive, 1 died (due to multiorgan failure) 1 transient cardiorespiratory event No other adverse effect |
(157) |
| During the 2 years follow up: 2 resolved pulmonary hypertension No long-term transplant-related adverse effect |
(158) | ||||||||
HAECs, human amnion epithelial cells.